Impact Biomedical (IBO) Income from Non-Controlling Interests (2022 - 2026)
Impact Biomedical's (IBO) quarterly Income from Non-Controlling Interests came in at $3000.0 in Q1 2026, up 127.27% YoY from $1320.0 in Q1 2025, and up 160.0% on a QoQ basis from -$5000.0 in Q3 2025.
Impact Biomedical (IBO) Income from Non-Controlling Interests (2022 - 2026) Analysis & Trends
Impact Biomedical (IBO) has 5 years of Income from Non-Controlling Interests data on file, last reported at $3000.0 in Q1 2026.
- Quarterly Income from Non-Controlling Interests rose 127.27% year-over-year to $3000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$19000.0 (up 48.65% YoY) and the FY2024 annual result came in at -$62000.0, up 12.68% from the prior year.
- Income from Non-Controlling Interests grew to $3000.0 in Q1 2026, from -$5000.0 in the prior quarter.
- In the past five years, Income from Non-Controlling Interests ranged from a high of $200000.0 in Q4 2022 to a low of -$192000.0 in Q1 2023.
- A 5-year average of -$17800.0 and a median of -$15000.0 in 2023 frame the typical range for Income from Non-Controlling Interests.
- Annual changes were most pronounced in 2025 — Income from Non-Controlling Interests sank 220.0% — and 2026, when it surged 127.27%.
- Tracing IBO's Income from Non-Controlling Interests over 5 years: stood at $200000.0 in 2022, then plunged by 113.0% to -$26000.0 in 2023, then advanced by 3.85% to -$25000.0 in 2024, then soared by 80.0% to -$5000.0 in 2025, then jumped by 160.0% to $3000.0 in 2026.
- The last three Income from Non-Controlling Interests figures came in at $3000.0 (Q1 2026), -$5000.0 (Q3 2025), and -$6000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 63.60 Mn |
| 10 | Impact Biomedical | 49.54 Mn | 49.53 Mn | 2,000.00 | -1,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1,000.00 |
| Mar 31, 2026 | 3,000.00 |
| Sep 30, 2025 | -5,000.00 |
| Jun 30, 2025 | -6,000.00 |
| Mar 31, 2025 | -11,000.00 |
| Dec 31, 2024 | -25,000.00 |
| Sep 30, 2024 | -6,000.00 |
| Jun 30, 2024 | 5,000.00 |
| Mar 31, 2024 | -36,000.00 |
| Dec 31, 2023 | -26,000.00 |
| Sep 30, 2023 | -15,000.00 |
| Jun 30, 2023 | -19,000.00 |
| Mar 31, 2023 | -192,000.00 |
| Dec 31, 2022 | 200,000.00 |
| Sep 30, 2022 | -67,000.00 |
| Jun 30, 2022 | -67,000.00 |